Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Copaiba

Phase 1Small molecule

IInstituto Nacional de Cancer, Brazil

Copaiba is one of 25 small molecule programs targeting Radiotherapy. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

24

Competitors

Pipeline

Status by Indication[3][1]

Indication

RadiotherapyActive, not recruiting

RadiotherapyPhase 1

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Radiotherapy

#DrugCompanyPhaseTrials

Medrol

Erbitux

Bavencio

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Imfinzi

Tecentriq

Eloxatin

Avastin

Abraxane

Bristol-Myers Squibb

Gemzar

Johnson & Johnson

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Radiotherapy

NCT05308732

Clinical

Trials by Indication[1]

Radiotherapy1 trial

Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy

Active, not recruiting·IInstituto Nacional de Cancer, Brazil·Phase 1·NCT05308732·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Copaiba. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Copaiba compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Copaiba. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Instituto Nacional de Cancer, Brazil company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IInstituto Nacional de Cancer, Brazil

Related News